Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.

[1]  Prashanthan Sanders,et al.  Catheter Ablation of Long‐Lasting Persistent Atrial Fibrillation: Clinical Outcome and Mechanisms of Subsequent Arrhythmias , 2005, Journal of cardiovascular electrophysiology.

[2]  K. Chandrasekaran,et al.  High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. , 2005, Journal of the American College of Cardiology.

[3]  M. Chung,et al.  C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion , 2005, Heart.

[4]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[5]  C. Pandozi,et al.  N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. , 2005, Journal of the American College of Cardiology.

[6]  Roger D. White,et al.  Prospective, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic biphasic cardioversion of atrial fibrillation. , 2005, Heart rhythm.

[7]  D. Kremastinos,et al.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. , 2005, The American journal of cardiology.

[8]  F. Cosío,et al.  Determining inferior vena cava-tricuspid isthmus block after typical atrial flutter ablation. , 2005, Heart rhythm.

[9]  G. Lip,et al.  Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. , 2004, The American journal of cardiology.

[10]  R. Page,et al.  Early Recurrence of Atrial Fibrillation: , 2004, Journal of cardiovascular electrophysiology.

[11]  M. Böhm,et al.  Impact of Biphasic Electrical Cardioversion of Atrial Fibrillation on Early Recurrent Atrial Fibrillation and Shock Efficacy , 2004, Journal of cardiovascular electrophysiology.

[12]  J. Dernellis,et al.  Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.

[13]  M. Silver,et al.  Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. , 2004, Preventive cardiology.

[14]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[15]  R. Goldberg,et al.  Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. , 2003, The American journal of cardiology.

[16]  C. Lau,et al.  Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. , 2003, The American journal of cardiology.

[17]  Ottavio Alfieri,et al.  Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. , 2003, Journal of the American College of Cardiology.

[18]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[19]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[20]  R. Kerber,et al.  Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. , 2002, Journal of the American College of Cardiology.

[21]  S. Humphries,et al.  Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release , 2002, Heart.

[22]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[23]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[24]  L. Køber,et al.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.

[25]  J Haaksma,et al.  Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? , 1998, Journal of the American College of Cardiology.

[26]  C. Hack,et al.  Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. , 1997, Circulation.

[27]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[28]  H. Crijns,et al.  Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. , 1996, Archives of internal medicine.

[29]  J. Tijssen,et al.  Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. , 1993, The American journal of cardiology.

[30]  I. V. Van Gelder,et al.  Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. , 1991, The American journal of cardiology.

[31]  H. Crijns,et al.  Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. , 1991, The American journal of cardiology.

[32]  L. Rydén,et al.  Chronic atrial fibrillation. Long-term results of direct current conversion. , 2009 .

[33]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .